<DOC>
	<DOCNO>NCT00701727</DOCNO>
	<brief_summary>This prospective , placebo-controlled , cross-over trial compare effect approximately 7 week placebo treatment 7 week ezetimibe ( 10mg/day ) treatment several parameter reverse cholesterol transport ( RCT ) men post-menopausal woman diagnose hypercholesterolemia . The primary hypothesis ezetimibe treatment increase excretion endogenous ( plasma-derived ) cholesterol fecal sterol , secondary hypothesis significant increase de novo cholesterol synthesis , treatment increase cholesterol efflux tissue bloodstream , increase global RCT .</brief_summary>
	<brief_title>Ezetimibe Reverse Cholesterol Transport ( RCT ) Pilot Study</brief_title>
	<detailed_description>The study compare effect approximately 7 week placebo treatment 7 week ezetimibe ( 10mg/day ) : 1 ) efficiency endogenous ( plasma-derived ) cholesterol excretion ( % /day ) 2 ) de novo cholesterol ( DNC ) synthesis ( ( % /day ) 3 ) cholesterol efflux tissue blood ( Ra ) , 4 ) global RCT ( efflux tissue excrete fecal sterol ) . Subjects receive 7 week either treatment placebo , undergo RCT DNC measurement , take 10 day , cross-over alternate placebo treatment additional 7 week , follow second set RCT DNC measurement .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>male , nonsmoker , 2175 year age female , nonsmoker , 4075 year age postmenopausal woman , define lack menses least 2 year age &gt; 55 , OR history document bilateral oophorectomy , confirm elevate FSH screen lowdensity lipoprotein ( LDL ) concentration 130200 mg/dL . triglyceride ( TG ) concentration &lt; 350 mg/dL , inclusive highdensity lipoprotein ( HDL ) 3060 mg/dL men 40 70 mg/dL woman ability give inform consent Subject history diabetes mellitus , active hepatitis , gall bladder disease , gastric ileal bypass surgery , irritable bowel syndrome , gastrointestinal disorder/condition associate malabsorption , clinically significant abnormality screen ( prestudy ) physical examination laboratory test . Screening laboratory test hematocrit &lt; 30 % , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 2*upper limit normal , abnormal thyroidstimulating hormone ( TSH ) , fast glucose &gt; =126mg/dL renal impairment creatinine clearance ( CRCl ) &lt; 80ml/min treatment within last 2 month drug know alter lipid metabolism include beta blocker , thiazide diuretic , bile acid resin , statin , ezetimibe , niacin , fibrates , plant stanol ester ( eg Benecol , phyto sterol ) fishoils history know coronary heart disease ( CHD ) , stroke prior revascularization procedure peripheral vascular disease history allergy egg soy product current recent ( past 12 month ) drug abuse alcohol abuse . Alcohol use must limit 2 drinks/day ( 1 drink=12 oz beer , 5 oz wine , 1.5 oz hard liquor ) . Subject must willing avoid large daytoday fluctuation alcohol intake . participation another clinical trial exposure investigational agent within 30 day prior Visit 1 Individual condition Principal Investigator believe would interfere his/her ability provide inform consent , comply study instruction , might confound interpretation study result , put subject undue risk</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>metabolic disease</keyword>
	<keyword>metabolic disorder</keyword>
	<keyword>dyslipidemias</keyword>
	<keyword>lipid metabolism disorder</keyword>
</DOC>